ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,598,684 | -68.1% | 279,981 | -63.9% | 0.00% | -50.0% |
Q2 2023 | $23,850,305 | -45.5% | 775,872 | -36.2% | 0.00% | -60.0% |
Q1 2023 | $43,789,205 | +79.2% | 1,215,354 | +96.5% | 0.01% | +66.7% |
Q4 2022 | $24,440,749 | +1.7% | 618,440 | +3.4% | 0.01% | 0.0% |
Q3 2022 | $24,030,000 | +7.4% | 598,061 | +12.3% | 0.01% | 0.0% |
Q2 2022 | $22,384,000 | -66.5% | 532,445 | -68.9% | 0.01% | -57.1% |
Q1 2022 | $66,744,000 | +418.9% | 1,713,133 | +430.7% | 0.01% | +366.7% |
Q4 2021 | $12,863,000 | +48.1% | 322,781 | +34.3% | 0.00% | +50.0% |
Q3 2021 | $8,687,000 | -68.8% | 240,379 | -64.6% | 0.00% | -66.7% |
Q2 2021 | $27,834,000 | +101.2% | 679,051 | +114.1% | 0.01% | +100.0% |
Q1 2021 | $13,836,000 | -53.1% | 317,205 | -46.2% | 0.00% | -62.5% |
Q4 2020 | $29,497,000 | +514.4% | 589,341 | +416.3% | 0.01% | +700.0% |
Q3 2020 | $4,801,000 | -89.5% | 114,149 | -87.9% | 0.00% | -93.8% |
Q2 2020 | $45,729,000 | – | 941,905 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |